Advanced

Increased basal ganglia binding of 18F-AV-1451 in patients with progressive supranuclear palsy

Smith, Ruben LU ; Schain, Martin; Nilsson, Christer LU ; Strandberg, Olof LU ; Olsson, Tomas LU ; Hägerström, Douglas LU ; Jögi, Jonas LU ; Borroni, Edilio; Schöll, Michael LU and Honer, Michael, et al. (2017) In Movement Disorders 32(1). p.108-114
Abstract

Background: Progressive supranuclear palsy (PSP) is difficult to diagnose accurately. The recently developed tau PET tracers may improve the diagnostic work-up of PSP. Methods: Regional tau accumulation was studied using 18F-AV-1451 PET in 11 patients with PSP and 11 age-matched healthy controls in the Swedish BioFinder study. Results: 18F-AV-1451 standard uptake volume ratios were significantly higher in the basal ganglia in PSP patients when compared with controls (globus pallidus 1.75 vs 1.50; putamen 1.51 vs 1.35). Retention in the basal ganglia was correlated with age in both groups (r=.43-.78, P<.05). In PSP, we observed a significant correlation between clinical deterioration measured with the PSP rating... (More)

Background: Progressive supranuclear palsy (PSP) is difficult to diagnose accurately. The recently developed tau PET tracers may improve the diagnostic work-up of PSP. Methods: Regional tau accumulation was studied using 18F-AV-1451 PET in 11 patients with PSP and 11 age-matched healthy controls in the Swedish BioFinder study. Results: 18F-AV-1451 standard uptake volume ratios were significantly higher in the basal ganglia in PSP patients when compared with controls (globus pallidus 1.75 vs 1.50; putamen 1.51 vs 1.35). Retention in the basal ganglia was correlated with age in both groups (r=.43-.78, P<.05). In PSP, we observed a significant correlation between clinical deterioration measured with the PSP rating scale and standard uptake volume ratios in the globus pallidus (r=.74, P<.05). However, no 18F-AV-1451 retention was observed in the cerebral cortex or white matter of either PSP patients or controls, and autoradiography did not reveal any specific binding of AV-1451 to PSP tau aggregates. Conclusion: We found higher 18F-AV-1451 retention in the basal ganglia of PSP patients when compared with healthy elderly controls, but also increases with age in both controls and patients. As a result of the overlap in retention between diagnostic groups and the age-dependent increase present also in controls, 18F-AV-1451 PET might not reliably distinguish individual patients with PSP from controls. However, further studies are needed to evaluate whether 18F-AV-1451 PET might be useful as a progression marker in clinical PSP trials.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Basal ganglia, Positron emission tomography, Progressive supranuclear palsy, Tau
in
Movement Disorders
volume
32
issue
1
pages
108 - 114
publisher
John Wiley & Sons
external identifiers
  • scopus:84995567000
  • wos:000398265600017
ISSN
0885-3185
DOI
10.1002/mds.26813
language
English
LU publication?
yes
id
0ad9c6ae-4d5a-46e8-ad4a-d8f9c0dc7fd2
date added to LUP
2016-12-02 13:58:02
date last changed
2018-01-14 04:27:46
@article{0ad9c6ae-4d5a-46e8-ad4a-d8f9c0dc7fd2,
  abstract     = {<p>Background: Progressive supranuclear palsy (PSP) is difficult to diagnose accurately. The recently developed tau PET tracers may improve the diagnostic work-up of PSP. Methods: Regional tau accumulation was studied using <sup>18</sup>F-AV-1451 PET in 11 patients with PSP and 11 age-matched healthy controls in the Swedish BioFinder study. Results: <sup>18</sup>F-AV-1451 standard uptake volume ratios were significantly higher in the basal ganglia in PSP patients when compared with controls (globus pallidus 1.75 vs 1.50; putamen 1.51 vs 1.35). Retention in the basal ganglia was correlated with age in both groups (r=.43-.78, P&lt;.05). In PSP, we observed a significant correlation between clinical deterioration measured with the PSP rating scale and standard uptake volume ratios in the globus pallidus (r=.74, P&lt;.05). However, no <sup>18</sup>F-AV-1451 retention was observed in the cerebral cortex or white matter of either PSP patients or controls, and autoradiography did not reveal any specific binding of AV-1451 to PSP tau aggregates. Conclusion: We found higher <sup>18</sup>F-AV-1451 retention in the basal ganglia of PSP patients when compared with healthy elderly controls, but also increases with age in both controls and patients. As a result of the overlap in retention between diagnostic groups and the age-dependent increase present also in controls, <sup>18</sup>F-AV-1451 PET might not reliably distinguish individual patients with PSP from controls. However, further studies are needed to evaluate whether <sup>18</sup>F-AV-1451 PET might be useful as a progression marker in clinical PSP trials.</p>},
  author       = {Smith, Ruben and Schain, Martin and Nilsson, Christer and Strandberg, Olof and Olsson, Tomas and Hägerström, Douglas and Jögi, Jonas and Borroni, Edilio and Schöll, Michael and Honer, Michael and Hansson, Oskar},
  issn         = {0885-3185},
  keyword      = {Basal ganglia,Positron emission tomography,Progressive supranuclear palsy,Tau},
  language     = {eng},
  number       = {1},
  pages        = {108--114},
  publisher    = {John Wiley & Sons},
  series       = {Movement Disorders},
  title        = {Increased basal ganglia binding of <sup>18</sup>F-AV-1451 in patients with progressive supranuclear palsy},
  url          = {http://dx.doi.org/10.1002/mds.26813},
  volume       = {32},
  year         = {2017},
}